Recursion Pharmaceuticals, Inc.(RXRX)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
RXRX | 1.84 B | -3.44x | -60.10% | - | $-1.00 | -56.58% | 7.28 | - | $7.18 | $2.77 |
FOLD | - | - | - | - | - | - | - | - | - | - |
VRTX | 141.42 B | 32.50x | 12.50% | 35.00% | $17.17 | 23.54% | 9.77 | - | - | - |
ALNY | 35.39 B | 46.08x | 66.90% | 16.13% | $5.74 | 96.56% | 2.21 | - | $495.55 | $197.81 |
ARWR | 12.22 B | -38.96x | 1.71% | -47.79% | $-2.22 | -55.21% | 2.96 | - | $95.49 | $22.73 |
CRSP | 5.46 B | -12.15x | 10.41% | - | $-4.65 | -26.10% | 0.45 | - | $78.48 | $44.12 |
Peer Valuation & Performance Analysis
Peer group analysis for Recursion Pharmaceuticals, Inc. (RXRX) compared to its primary competitors (including FOLD, VRTX, ALNY) reveals distinct metrics. RXRX trades at a valuation discount relative to its competitors, with a P/E ratio of -3.4x versus the peer average of 4.7x (representing a 173% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, RXRX's revenue growth of -60.1% lags behind the peer average of 9.1%, indicating potential market share losses or slower industry adoption.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• RXRX ranks #0 in P/E ratio, #5 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $3.44 | $3.45 | $3.29 | $3.44 | 13,630,800 | +0.15% |
| 2026-09-02 | $3.34 | $3.49 | $3.29 | $3.38 | 14,052,700 | +1.20% |
| 2026-09-01 | $3.34 | $3.38 | $3.28 | $3.33 | 9,991,900 | -0.30% |
| 2026-08-31 | $3.31 | $3.41 | $3.25 | $3.40 | 13,903,400 | +2.87% |
| 2026-08-28 | $3.40 | $3.45 | $3.31 | $3.34 | 10,560,600 | -1.76% |
| 2026-08-27 | $3.52 | $3.55 | $3.42 | $3.44 | 10,986,800 | -2.13% |
| 2026-08-26 | $3.51 | $3.55 | $3.43 | $3.49 | 12,978,400 | -0.57% |
| 2026-08-25 | $3.27 | $3.59 | $3.26 | $3.56 | 22,516,700 | +8.87% |
| 2026-08-24 | $3.42 | $3.44 | $3.21 | $3.25 | 15,155,100 | -4.97% |
| 2026-08-21 | $3.39 | $3.63 | $3.37 | $3.50 | 22,898,500 | +3.24% |
| 2026-08-20 | $3.40 | $3.46 | $3.27 | $3.34 | 21,453,700 | -1.76% |
| 2026-08-19 | $3.27 | $3.50 | $3.19 | $3.50 | 30,198,700 | +6.87% |
| 2026-08-18 | $3.03 | $3.10 | $2.92 | $3.09 | 16,300,500 | +1.98% |
| 2026-08-17 | $3.12 | $3.16 | $3.08 | $3.11 | 10,621,600 | -0.32% |
| 2026-08-14 | $3.30 | $3.31 | $3.14 | $3.16 | 10,508,600 | -4.24% |
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.